Predicting recurrence in pancreatic neuroendocrine tumours: role of ARX and alternative lengthening of telomeres (ALT)
Histopathology · 2023
DOI: 10.1111/his.14996 ↗Kurz gefasst
Fachartikel in der Zeitschrift Histopathology, 2023. Verfasst von Azfar Neyaz und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Massachusetts General Hospital, Boston, MA, USA. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Pancreatic Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Abstract (Originalsprache)
Background
While many pancreatic neuroendocrine tumours (PanNET) show indolent behaviour, predicting the biological behaviour of small nonfunctional PanNETs remains a challenge. Nonfunctional PanNETs with an epigenome and transcriptome that resemble islet alpha cells (ARX‐positive) are more aggressive than neoplasms that resemble islet beta cells (PDX1‐positive). In this study, we explore the ability of immunohistochemistry for ARX and PDX1 and telomere‐specific fluorescence in situ hybridisation (FISH) for alternative lengthening of telomeres (ALT) to predict recurrence.
Methods
Two hundred fifty‐six patients with PanNETs were identified, and immunohistochemistry for ARX and PDX1 was performed. Positive staining was defined as strong nuclear staining in >5% of tumour cells. FISH for ALT was performed in a subset of cases.
Results
ARX reactivity correlated with worse disease‐free survival (DFS) ( P = 0.011), while there was no correlation between PDX1 reactivity and DFS ( P = 0.52). ALT‐positive tumours ( n = 63, 31.8%) showed a significantly lower DFS ( P < 0.0001) than ALT‐negative tumours ( n = 135, 68.2%). ARX reactivity correlated with ALT positivity ( P < 0.0001). Among nonfunctional tumours, recurrence was noted in 18.5% (30/162) of ARX‐positive tumours and 7.5% (5/67) of ARX‐negative tumours. Among WHO grade 1 and 2 PanNETs with ≤2 cm tumour size, 14% (6/43) of ARX‐positive tumours recurred compared to 0 of 33 ARX‐negative tumours and 33.3% (3/9) ALT‐positive tumours showed recurrence versus 4.4% (2/45) ALT‐negative tumours.
Conclusion
Immunohistochemistry for ARX and ALT FISH status may aid in distinguishing biologically indolent cases from aggressive small low‐grade PanNETs, and help to identify patients who may preferentially benefit from surgical intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Massachusetts General Hospital, Boston, MA, USA.
- David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Boston, MA, USA.
- Massachusetts General Hospital Cancer Center, Boston, MA, USA.
- Department of Medicine, Boston Medical Center, Boston, MA, USA.
- Department of Surgery, Massachusetts General Hospital, Boston, MA, USA.
- Department of Pathology, Brigham and Women's Hospital, Boston, MA, USA.
ORCID-Profile: Azfar Neyaz, Steffen Rickelt, Theodoros P Michelakos, Paige H Parrack, Deepa T Patil
Zitieren
APA
Neyaz, A., Crotty, R., Rickelt, S., Pankaj, A., Stojanova, M., Michelakos, T. P., Sekigami, Y., Kontos, F., Parrack, P. H., Patil, D. T., Heaphy, C. M., Ferrone, C. R., & Deshpande, V. (2023). Predicting recurrence in pancreatic neuroendocrine tumours: role of ARX and alternative lengthening of telomeres (ALT). Histopathology. https://doi.org/10.1111/his.14996
Vancouver
Neyaz A, Crotty R, Rickelt S, Pankaj A, Stojanova M, Michelakos TP, et al. Predicting recurrence in pancreatic neuroendocrine tumours: role of ARX and alternative lengthening of telomeres (ALT). Histopathology. 2023. doi:10.1111/his.14996
BibTeX
@article{Neyaz2023,
author = {Neyaz, Azfar and Crotty, Rory and Rickelt, Steffen and Pankaj, Amaya and Stojanova, Marija and Michelakos, Theodoros P and Sekigami, Yurie and Kontos, Filippos and Parrack, Paige H and Patil, Deepa T and Heaphy, Christopher M and Ferrone, Cristina R and Deshpande, Vikram},
title = {Predicting recurrence in pancreatic neuroendocrine tumours: role of ARX and alternative lengthening of telomeres (ALT)},
journal = {Histopathology},
year = {2023},
doi = {10.1111/his.14996}
}
EUVIMED